Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease.
The aim of this study was to compare the diagnostic value of skeletal AP and PSA with the skeletal scintigram in patients with prostatic cancer. PSA and skeletal AP were measured by Tandem-R-Ostase Assay (IRMA) and Tandem-R-PSA-Assay. 64 patients with prostatic cancer, 20 of them in stage D2 were involved. Patients with a prostatic cancer and bone metastases show remarkable increased skeletal AP concentration with a median concentration of 50ng/ml SAP and 95 ng/ml PSA. Patients without bone metastases have a lower median concentration of SAP at 10 ng/ml and PSA concentration of 40 ng/ml which is within the normal range. Six out of 20 patients at stage D2 showed a significant increase of SAP concentration and even of PSA before bone metastases were seen by skeletal scintigraphy. We conclude when skeletal metastases are assumed in patients with prostatic cancer, a combination of skeletal scintigramm and measurement of SAP seem to be of advantage to recognize patients with bone metastases earlier.
Oremek
G M
GM
University Hospital, Central Laboratory, Frankfurt/Main, Germany.
Kramer
W
W
Seiffert
U B
UB
Jonas
D
D
D000469:Alkaline Phosphatase / Q000378:metabolism*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000201:enzymology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D011877:Radionuclide Imaging
D000469:Alkaline Phosphatase